Cytochrome P450 Enzyme Inhibitors from Nature by Simone Badal et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Cytochrome P450 Enzyme  
Inhibitors from Nature  
Simone Badal, Mario Shields and Rupika Delgoda 
University of the West Indies/ 
Natural Products Institute 
Jamaica 
1. Introduction 
1.1 Cytochrome P450 
Cytochrome P450 (CYP) is a heme containing enzyme superfamily that catalyzes the 
oxidative biotransformation of lipophilic substrates to hydrophilic metabolites facilitating 
their removal from cells. The CYPs were first recognized by Martin Klingenberg 
(Klingenberg, 1958) while studying the spectrophotometric properties of pigments in a 
microsomal fraction prepared from rat livers. When a diluted microsomal preparation was 
reduced by sodium dithionite and exposed to carbon monoxide gas, a unique spectral 
absorbance band with a maximum at 450nm appeared.  The ferric ion in the resting heme, 
binds easily with CO following reduction, and the complex’s maximal absorbance band, 
unique amongst hemeproteins, serves as the signature of CYP enzymes.  
CYPs are mostly located in the endoplasmic reticulum, and to some extent in mitochondrial 
fractions of hepatic and extra-hepatic tissues.  Even though these enzymes are ubiquitous in 
the body (Table 1), of the 18 families in mammals identified, 11 are expressed in a typical 
human liver (CYP1A2, CYP2A6, CYP2B6, CYP2C8/9/18/19, CYP2D6, CYP2E1, and 
CYP3A4/5).  In addition, five of these enzymes (CYPs 1A2, 2C9, 2C19, 2D6 and 3A4) 
expressed at high levels in the liver demonstrate a broad substrate selectivity which 
accounts for about 95% of drug metabolism (Nelson, 2009; Treasure, 2000). 
The metabolism of a drug can be altered by another drug or foreign chemical and  
such interactions can often be clinically significant. As a result, the FDA (Food and  
Drug Administration) and other regulatory agencies such as the Department of Health 
and Human Services (DHHS), Centers for Disease Control and Prevention (CDS)  
and Hazard Analysis Critical Control Point (HACCP) among others expect information on 
the relationship between each new drug to CYP enzymes (substrate, inhibitor and or 
inducer) making these enzymes vital in the process of drug discovery. One of the major 
concerns is avoiding drug interactions, an issue whose importance increases with the 
aging of population (Guengerich, 2003) along with the increase in the practice of 
polypharmacy.  
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Organ CYPs detected 
Nasal mucosa 2A6, 2A13, 2B6, 2C, 2J2, 3A 
Trachea 2A6, 2A13, 2B6, 2S1 
Lung 1A1, 1A2, 1B1, 2A6, 2A13, 2B6, 2C8, 2D6, 2E1, 2F1, 2J2, 2S1, 
3A4, 3A5, 4B1 
Oesophagus 1A1, 1A2, 2A, 2E1, 2J2, 3A5 
Stomach 1A1, 1A2, 2C, 2J2, 2S1, 3A4 
Small Intestine 1A1, 1B1, 2C9, 2C19, 2D6, 2E1,2J2, 2S1, 3A4, 3A5 
Colon 1A1, 1A2, 1B1, 2J2, 3A4, 3A5 
Table 1. Human cytochrome P450 genes expressed in different parts of the respiratory and 
gastrointestinal tracts (adopted from Ding and Kaminsky, 2003). 
1.2 Classification of CYP enzymes 
All eukaryotic CYPs except fungal CYP55s are membrane bound; 18 mammalian CYP 
enzyme structures are known and 15 of these are of human origin; [1A2, 2A6, 2A13, 2B4 
rabbit, 2B6, 2C5 rabbit, 2C8, 2C9, 2D6, 2E1, 2R1, 3A4, 7A1, 8A1, 19A1, 24A1 rat, 46A1, 51A1, 
(Nelson and Nebert, 2011)]. CYPs sharing >40% sequence identity are categorised within the 
same family while those with >55% sequence identity are placed within the same subfamily. 
The CYP superfamily members are named according to a nomenclature system that was 
established in the mid-1980s (Nebert et al., 1987), however, the last comprehensive revision 
was published in 1996 (Nelson et al., 1996).  
CYP2 is the largest CYP450 family in mammals with 13 subfamilies and 16 genes in humans. 
CYPs2C8, 2C9, 2C18 and 2C19 jointly metabolise more than 50 drugs whilst CYP2D6 
metabolises more than 70 drugs (Meyer and Zanger, 1997). CYP3A is the most abundantly 
expressed CYP450 gene in the human liver and gastrointestinal tract (Nelson, 1999) and is 
known to metabolise more than 120 commonly prescribed pharmaceutical agents.  
CYPs1Al and 1B1 are predominately expressed in extra-hepatic tissues (Guengerich and 
Shimada, 1991; Shimada et al., 1992) while CYP1A2 is expressed primarily in the liver. As a 
result, constitutive levels of CYP1A2 are much greater than those of CYPs1A1 and 1B1 
(Shimada et al., 1992; Shimada et al., 1994b) whose levels are usually induced by PAHs. All 3 
members of the CYP1 family are upregulated by halogenated and polycyclic aromatic 
hydrocarbons such as those found in cigarette smoke and charred food.  
1.3 Importance of CYP enzyme inhibition  
1.3.1 Involvement in drug interactions 
The metabolism of a drug can be altered by another drug or foreign chemical and such 
interactions can often be clinically significant. The observed induction and inhibition of CYP 
enzymes by various traditional remedies have led to the general acceptance that natural 
therapies can have adverse effects. This is contrary to the popular beliefs in countries where 
there is an active practice of ethnomedicine. Drug-herb interactions may involve 
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competitive, noncompetitive, or uncompetitive inhibition of drug metabolizing enzymes or 
enzyme induction by the phytopharmaceutical (Delgoda and Westlake, 2004). 
Several epidemiological surveys including ones conducted by our laboratory (Delgoda et al., 
2004; Delgoda et al., 2010; Picking et al., 2011) have indicated high usage of herbal medicines 
along with prescription medicines with low physician awareness. With over 80% of the 
prescription medicine users also seeking some form of herbal remedy in Jamaica, the 
chances of drug interactions rises and this prompted investigations into likely 
pharamacokinetic, metabolism based interactions between the two types of medicines.  
The CYP enzymes, responsible for the metabolism of over 90% of drugs in the market is 
unsurprisingly associated with numerous metabolism related drug interactions 
(Guengerich, 1997), including those of drugs and herbs (Ioannides, 2002; Delgoda and 
Westlake, 2004). The inhibition of CYP3A4 by fucocoumarins found in grapefruit juice 
leading to clinically observable toxicities with drugs and the induction of the same CYP3A4 
enzyme by ingredients found in St. John’s wort leading to subtherapeutic interferences with 
cycloporin provide suitable examples for the involvement of CYP enzymes in drug herb 
interactions. While clinical studies provide the ultimate proof for relevant drug interactions, 
in-vitro laboratory evaluations with CYP enzymes, has provided a convenient, economical 
and useful starting point for screening those herbs that may ultimately cause clinically 
observable drug interactions. Human liver microsomes, heterologously expressed enzymes 
and hepatocytes although with limitations, have provided convenient means for such initial 
assessements.  
In this chapter, we describe for the first time, the initial inhibitory impact of four commonly 
consumed infusions on six major CYP enzymes. Our findings support that the teas are 
moderate to weak CYP inhibitors and so we postulate that they would unlikely result in 
drug interactions. 
1.3.2 CYP inhibition and its relation to chemoprevention 
Approximately five decades of systematic drug discovery and development have 
established a reliable collection of chemotherapeutic agents (Yarbro, 1992; Chabner, 1991).  
These chemotherapeutic agents have assisted with numerous successes in the treatment and 
management of human cancers (Chabner et al., 1991).  
Chemoprevention is the ability of compounds to protect healthy tissues via the prevention, 
inhibition or reversal of caricnogenesis.  The inhibition of CYP1 enzymes is one such route 
among others that include the induction of cell cycle arrest, the induction of phase II 
enzymes and the inhibition of inflammatory. The CYP1 family has been linked with the 
activation of pro-carcinogens which is facilitated by the regulation of the aryl hydrocarbon 
receptor. As such research has shown that inhibiting CYP1 enzymes plays a key role in 
protecting healthy cells from the harmful effects of activated carcinogens. 
Among the polycyclic hydrocarbons that are activated into reactive metabolites by CYPs 
1A1 and 1B1 is benzo-a-pyrene [BaP]. Metabolites from BaP include phenols, polyphenols, 
quinines, epoxides and dihydrodiols. Among these dihydrodiols; (-)-benzo[a]pyrene-trans-
7,8-dihydrodiol (BPD) and (+)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti-
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BPDE) are carcinogenic, however the latter is the ultimate carcinogen as it has been shown 
to bind DNA predominantly at the N2-position of guanine to produce primarily N2-guanine 
lesions, benzo-a-pyrene 7,8-diol-9,10-epoxide-N2-deoxyguanosine (BPDE-N2-dG) adduct 
(Osborn et al., 1976). It is proposed that BPDE-N2-dG is linked to the high frequency of p53 
G→T transversions observed in lung cancer of smokers (Hainaut and Pfeifer, 2001; Pfeifer et 
al., 2002). Further mutations in the p53 gene have also been found and these include 
transversions, G→A and G→C (Shukla et al., 1997; Schiltz et al., 1999). Similar to the role of 
CYP1A1 in the activation of BaP is that of the aromatic amines; amino-3-methylimidazo[4,5-
f]quinoline (IQ), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3,8-
dimethylimidazo-[4,5-flquinoxaline (MeIQx). CYP1A2 plays an important role in the N-
oxidation of these aromatic amines which have been linked to colon and urothelium cancers 
(Landi et al., 1999), thus highlighting the role of CYP1 enzymes in carcinogenic activation 
and thus their potential as preventative targets. Fig.1 is a schematic representation of the 
process of carcinogenesis at the cellular level. 
 
Fig. 1. A schematic representation of carcinogenesis via the activation of CYP1 enzymes. 
Upon the activation of the pro-carcinogens by the CYP1 enzymes, they have the ability to 
bind to DNA, which can lead to mutations and then the formation of cancer cells. 
One of the first reported chemoprotectants was disulfiram (Stoner et al., 1997) which inhibited 
the action of dimethylhydrazine via the inhibition of CYP1 enzymes. Other chemopreventive 
agents are discussed by Chang and others (Chang et al., 2002) who report that Ginseng 
decreases the incidence of 7,12 dimethyldenz(a)anthracence (DMBA)-initiated tumorigenesis 
in mice via the inhibition of CYPs1A1, 1A2 and 1B1. Also, the flavanoid, galangin was found 
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to be an agonist of the aryl hydrocarbon receptor and consequently was responsible for an 
increased level of CYP1A1 expression, however this effect was counteracted by its ability to 
inhibit the enzyme directly and so is deemed an effective chemo-preventive agent (Ciolino and 
Yeh, 1999). Resveratrol was also found to exhibit chemo-preventive properties via the 
inhibition of CYP1A1 expression in vivo by preventing the binding of the AhR to promoter 
sequences that regulate the CYP1A1 transcription and also by the direct potent inhibition of 
CYPs1A1 and 1B1 (Ciolino et al., 1998; Chen et al., 2004).  
1.4 CYP inhibition and its relation to chemoprevention 
Bioactivity of isolates from the Jamaica plants, Amyris plumieri, Peperomia amplexicaulis, 
Spathelia sorbifolia and Picrasma excelsa are reported in this chapter. Amyris plumieri is found 
in the Caribbean, Central America and Venezuela and plants of this genus have been used 
in folk medicine against skin irritation while isolates have been found to exhibit anticancer 
and antimycobacterial properties (Fuente et al., 1991, Hartwell, 1968). Even though both 
Peperomia amplexicaulis and Spathelia sorbifolia are not commonly consumed in Jamaica, 
isolates from these plants have been shown to exhibit antiprotozoal, chemopreventive and 
anti-cancer activity (Mota et al., 2009; Cassady et al., 1990) and previously examined for CYP 
inhibitions (Badal et al., 2011; Shields et al., 2009) and overviewed in this chapter. Infusions 
of the plant Picrasma excelsa, known as Jamaican bitterwood tea, are commonly consumed to 
lower blood sugar levels in diabetics who are already on prescription medicines. All other 
plants investigated in this chapter; Rhytidophyllum tomentosa, Psidium guajava, Symphytium 
officinale, Momordica charantia are frequently consumed in the form of teas or the fruits of the 
appropriate plants. We therefore investigated the inhibition properties of these teas against 
a panel of CYP450 enzymes in order to assess the potential for drug interactions with co-
medicated pharmaceuticals.  
2. Materials and methods 
2.1 Chemicals 
All CYP substrates and metabolites were purchased from Gentest Corporation (Woburn, 
MA, U.S.A.). All other chemicals were purchased from Sigma-Aldrich (MO, U.S.A.). 
2.2 CYP microsomes 
Escherichia coli membranes expressing human CYP2D6, CYP3A4, CYP1A1, CYP1A2 and 
each containing P450 reductase, were a gift from Dr. Mark Paine and Prof. Roland Wolfe 
(University of Dundee, UK). CYP2C19 expressed in baculovirus-insect cells (supersomes) 
were purchased from Gentest Corporation, Woburn, MA 
2.3 Preparation of infusions from medicinal plants 
The selection of the plants for screening and method of preparation were based on the 
survey conducted by Delgoda et al (Delgoda et al., 2010). The teas were prepared by infusing 
100ml of boiling deionized water per 1g of dried, finely ground material (leaf, bark or wood 
chips), for 10 minutes. The resulting liquor was suctioned filtered through type 1 Watman 
www.intechopen.com
 
Enzyme Inhibition and Bioapplications 
 
44
filter paper. A portion of the filtrate was then centrifuged at 13000 × g for 5 minutes to 
remove suspended solids.  
2.4 Separation of active ingredients from medicinal plants 
Infusions were freeze dried and re-dissolved in water just prior to use, unless otherwise stated. 
25µl infusions were loaded onto a microsorb C18 column (ID 4.6mm, 25cm, 5m) and separated 
using the appropriate solvent systems using Varian Prostar HPLC system (Varian Inc. USA).  
2.5 CYP inhibition assays 
Routinely, appropriate volumes of potassium phosphate buffer (KPB), test inhibitor, CYP, 
and the substrates were added to a NADPH regenerating mixture and made up to 400 µL, 
and monitored fluorometrically on a continuous basis for 10mins as described elsewhere 
(Shields, 2009), using CYP450 substrates,3-[2-(N,N-Diethyl-N-methylamino)ethyl]-7-
methoxy-4methylcoumarin (AMMC), 7-Benzyloxy-4-trifluoromethylcoumarin (BFC), as 
substrates for CYP3A4 and CYP2D6 respectively and 7-ethoxy-3-cyanocoumarin (CEC) as 
substrate for CYPs 1A1, 1A2, 2C19 and 2C9. In other instances (as specified in each case), a 
96-well plate assay was employed as detailed in (Badal et al., 2011). Fluoroscence was 
monitored using a Varian Cary Eclipse Fluorescence spectrophotometer.  
Positive control experiments were conducted with varying concentrations of furafaylline 
(≥98%) (0.5-10µM), quinidine (≥90%, 1-50nM) and ketoconazole (≥98%) (2-100nM) with 
CYP1A2, CYP2D6 and CYP3A4 respectively.  
2.6 Data analysis 
IC50 and Ki values were determined by fitting the data in Sigma Plot (version 10.0) and 
enzyme kinetics module, using non linear regression analysis. The data listed represent the 
average values from three different determinations.  
3. Results 
3.1 Optimising experimental conditions 
To verify the accuracy of experimental techniques employed to detect CYP inhibition, assays 
with known inhibitors were carried out with furafylline (against CYP1A2), ketoconazole 
(against CYP1A1, CYP1B1 and CYP3A4), (−)-N-3-benzyl-phenobarbital (NBPB, against 
CYP2C19) and quinidine (against CYP2D6) and the obtained IC50 values (0.8±0.2, 0.04±0.01, 
6.3±1.7, 0.06±0.01, 0.3±191 0.01, and 0.03±0.01μM respectively) compared well with 
published values (0.99, b10, b10, 0.06, 0.25 and 0.01μM respectively; Shields, 2009; Badal et 
al., 2011; Powrie, 2010; Stresser et al., 2004; Cali, 2003 and McLaughlin et al., 2008).  
3.2 Natural products as CYP inhibitors 
Several classes of natural products were examined in our laboratory for their inhibitory 
properties towards CYP450 enzymes. Chromene amides (CAs) isolated from Amyris 
plumieri, quassinoids isolated from Picrasma excelsa, anhydrosorbifolin isolated from 
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Spathelia sorbifolia and chroman 6 isolated from Peperomia amplexicaulis. Structures for these 
can be seen in Figs. 2.1, 2.2 and 2.3 and in addition obtained IC50s can be seen in Table 2. 
Both CA1 and quassin exhibited the most potency against CYP1A1. Both Anhydrosorbifolin 
and chroman 6 and CAs, 1, 2 and 3moderately (IC50 between 1 and 10μM) inhibited the 
activities of CYP1 family.  
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Fig. 2.2. Quassinoids 
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but-2-enyl)-2-(4-methyl-penta-1,3-
dienyl)-chroman-6-carboxylic acid 
Anhydrosorbifolin 
Fig. 2.3. Others 
 
Compounds CYP isoforms 
1A1 1A2 1B1 2C9 2C19 2D6 3A4 
CA1 1.31 ± 0.42
Ki =0.37 
32.80 ± 
4.45 
15.36 ± 0.42 nd 0.77 ± 
0.39 
2.22 ± 
0.69 
1.14±0.4
8 
CA2 1.63 ± 0.53
Ki=2.40 
6.25 ± 
1.85 
37.04 ± 1.51 nd 1.09 ± 
0.52 
359.88 ± 
144.55 
15.48±0.
45 
CA3 2.43 ± 0.62
Ki=1.39 
189.84 ± 
7.60 
179.30 ± 20.5 nd 2.43 ± 
0.28 
11.70 ± 
5.40 
122.93±5
.95 
CA4 14.39 ± 
7.40 
18.59 ± 
0.67 
18.14 ± 1.02 nd 2.55 ± 
1.85 
84.40 ± 
3.5 
7.63±1.2
6 
Quassin 
 
9.2 
Ki=10.8 
57.6 ND 92.5 262.5 217.8 47.0 
Neoquassin 
 
11.9 
Ki=11.3 
85.3 ND 80.6 113.4 184.1 24.5 
Anhydro-
sorbifolin 
4.9 1.9 1.4 nd nd nd nd 
Chroman 6 2.1 5.8 5.6 nd nd nd nd 
Table 2. Summary of IC50 and Ki values (µM) obtained from the interaction of isomers of 
chromene amides, quassinoids along with anhydrosorbifolin and chroman 6 using 
heterologously expressed CYP microsomes. ND: Not determined due to intrinsic 
fluorescence and quenching/enhancement of the metabolite nd: not done 
3.3 Herbal infusions with CYP inhibitors 
Hot water infusions of five popular herbs; Rhytidophyllum tomentosa, Psidium guajava, 
Symphytium officinale, Momordica charantia and Picrasma excelsa were characterized for impact 
as shown in Fig.3 and calculated IC50 values on the activities of CYP enzymes are shown in 
Table 3.  
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Fig. 3. Inhibition of CYP activity by medicinal plant infusions.  
3.4 Identification of active ingredients 
Due to the potency displayed against the activities of CYP450 enzymes, Psidium guajava was 
selected for further characterization. Preliminary separation of the freeze-dried extract of 
Psidium guajava by reverse phase HPLC (see Fig.4) revealed several resolved peaks and LC-
MS analysis at the same time and the results are summarized in Table 3. Two peaks were 
identified as quercetin and hyperin whose structures are shown in Fig.5 and these displayed 
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50% inhibition against the activity of CYP2D6 enzymes as shown in Fig.6. Previously 
modelled active site of CYP1A1 with bound quassin is displayed in Fig.7 where key residues 
in the enzyme are identified; Asp313, Thr11, Ser124, Phe123, Ile386 and Leu496 in the 
interaction between quassin and neoquassin.  
Inhibition of CYP activity by Rhytidophyllum tomentosa infusion (A); Psidium guajava (B); 
Momordica charantia (C); and Symphytium officinale (D). Different volumes of reconstituted 
freeze-dried infusion were added to the incubation mixture, along with the CYP isoform, 
substrate, and 6GPDH, and monitored fluorometrically over time, as described in Materials 
and Methods. Control enzyme activity (mean ± SEM) for CYP3A4, CYP1A1, CYP2D6, 
CYP1A2, CYP2C19, and CYP2C9 was 0.147 ± 0.037, 0.907 ± 0.095, 0.005 ± 0.000, 1.45 ± 0.04, 
0.054 ± 0.016, and 0.057 ± 0.004μM/min/pmol of CYP, respectively. Curves for CYP2D6 and 
CYP1A2 in for Memordica charantia (C) and for CYP3A4 in by Symphytium officinale (D) were 
not included because their IC50 values exceeded 200g/mL. 
 
Isoform IC50 (g/mL) 
Rhytidophyllum 
tomentosa 
Psidium 
guajava 
Momordica 
charantia 
Symphytium 
officinale 
Picrasma 
excelsa* 
CYP1A1 10.2 4.9 137.1 24.0 15.0 
CYP1A2 28.3 24.0 >200.0 40.3 19.1 
CYP2D6 158.0 26.3 >200.0 127.9 >200 
CYP2C19 93.8 23.3 91.0 172.7 199.9 
CYP3A4 178.1 48.7 82.3 >200.0 122.8 
*Values for Picrasma excelsa were obtained from Shields et al, 2008. 
Table 3. Summary of IC50 values obtained for the extracts from Fig. 2 
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Fig. 4. HPLC profile of Psidium guajava extract 
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Quercetin Hyperin 
Fig. 5. Structures of quercetin and hyperin (quercetin-3-D-galactoside). 
 
 
 
 
 
Fig. 6. HPLC profile of Psidium guajava (adapted from Shields et al., 2009). 
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Fig. 7. Interaction of quassinoids with CYP1A1 
4. Discussion 
Cytochrome P450 enzymes have been of particular interest in the field of drug discovery 
for numerous reasons including the involvement of these enzymes in the metabolism of 
over 95% of the drugs on the market and the potential of drug-drug interaction through 
metabolism. CYP1 family which is under the regulation of the aryl hydrocarbon receptor 
have been extensively researched and implicated in drug resistance as well as 
carcinogenesis. CYP1B1 in particular, found in elevated levels in cancer tissues such as 
those in colon is thought to provide a novel pathway for drug discovery and optimisation 
for cancer treatment. Inhibitors of the activities of CYP1 enzymes are now accepted as 
potential chemoprotectants by preventing the activation of polycyclic aromatic 
hydrocarbons such as benzo-a-pyrene. Catalysed by CYP1A1 and CYP1B1, metabolites of 
this pro-carcinogen, (+)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti-
BPDE) and that 3-hydroxybenzo [a]pyrene (3HBaP) have been shown to bind to DNA 
predominantly at the N2-position of guanine to produce N2-guanine lesions, benzo-a-
pyrene 7,8-diol-9,10-epoxide-N2-deoxyguanosine (BPDE-N2-dG) adduct (King et al., 1976). 
Thus inhibitors of CYP1 enzymes hold the potential to prevent the formation of such 
damaging precursors that initiate malignant cancers of the breast, colon, lung and 
urothelium among others. 
In this chapter we highlight the potential of a few natural products abundant in the 
Caribbean: chromene amides isolated from Amyris plumieri, quassinoids isolated from 
Picrasma excelsa, anhydrosorbifolin isolated from Spathelia sorbifolia and chroman 6 isolated 
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from Peperomia amplexicaulis. We also report for the first time bioactive screening of CYP 
enzymes in the presence of five aqueous infusions of popularly used herbs; Rhytidophyllum 
tomentosa, Psidium guajava, Symphytium officinale, Momordica charantia and Picrasma excelsa. 
Potent and selective inhibition of the CYP1 enzymes were found amongst the investigated 
natural compounds in particular chromene amides and quassinoids. CA1 displayed potent 
inhibition against the activity of CYP1A1, with a Ki of 0.37μM and an IC50 value of 1.31μM 
while quassin inhibited this enzyme with an IC50 value of 9.2μM and Ki of 10.8μM with 
selectivity extended throughout all CYP enzymes investigated except CYP2C19 for CA1. 
The degree of potency and selectivity with which both compounds inhibited this enzyme 
warrants further research as possible chemoprotectants. Previously known and studied 
natural compounds deemed to possess chemoprotective properties due to their ability to 
inhibit CYP1A1 include; quercetin (IC50=1.36μM, Leung et al., 2007), curcumin (IC50=20μM), 
demethoxycurcumin (IC50=21μM), ε-viniferin (IC50=1μM), resveratrol (IC50=30μM), and 
sanguinarine (Ki =2μM). Both test compounds compare well with these known 
chemoprotectants and thus warrant further research.  
Both CYPs 1A1 and 1A2 share approximately 70% similarity in amino acid and the 
specificity with which inhibition targeted towards CYP1A1 activity is noticeable in the 
compounds CA1, CA3 and quassin. As such we unlocked the interaction between quassin 
and CYP1A1 in previous publication (Shields et al., 2009). One of the first active site models 
for CYP1A1 was demonstrated with quasin and important residues were highlighted; 
Asp313, Thr11, Ser124, Phe123, Ile386 and Leu496 as shown in Fig.7 as being critical for 
binding quassinoids. 
CYP1B1 has been drawing keen interest for novel and anticancer therapeutics. Findings of 
the over-expression of CYP1B1 in many tumour tissues compared with normal surrounding 
cells, have led to the search for pro-drugs reliant on CYP1B1 metabolism for the conversion 
into cytotoxic therapeutics. Although the role of such over- expression is yet to be fully 
understood, it has been linked with drug resistance and in the promotion of cell survival 
(Martinez et al., 2008). The modification in the expression levels of CYP1B1 has been shown 
to modulate tumour progression (Castro et al., 2008) and thus specific inhibitors are 
expected to be of therapeutic/preventive benefit. Although the potency and the specificity 
of the chromene amides examined this chapter against CYP1B1 is not particularly high, 
structure-activity relations may guide towards chromene amides with putative 
improvement. Anhydrosorbifolin and chroman 6 displayed the most potency against this 
enzyme deeming further investigations worthwhile. 
Little impact towards the CYP1 family was observed in the presence of CA2 which could 
be due to the isopropyl group on this chromene amide, compared with CA1. Even though 
the Ki against CYP1A1 was increased (to 2.63μM), the IC50 value remained more or less 
the same as CA1 (1.63μM), displayed moderate to low potency against CYPs 1A2 and 1B1. 
The structural change made to CA2 was more significant in binding CYP2D6 as the 
inhibition dropped over a 100 times (IC50=360μM for CA2 vs 2μM for CA1). Hence, CA2 
displayed characteristics of a useful molecular probe where all significant drug 
metabolizing enzymes can be inhibited except for the activity of CYP2D6. Chain 
elongation and the loss of branching in the n-propyl end unit to form CA3, have a 
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dramatic impact on the affinity to CYP1A2 and CYP1B1. The inhibition potency dropped 
6 folds against CYP1A2 (from 32.8μM for CA1 to 189.8μM for CA3) and 10 folds against 
CYP1B1 (from15.4μM to 179.3μM). Thus, CA3 appears to show increased selectivity in its 
inhibition against CYP1A1. Exploring other side groups as well as shifting the position of 
the existing side groups can be explored in hopes of increasing the potency of CAs 
towards the activity of CYP1B1  
There is a large consumption of natural medicines alone and concurrently with prescription 
medicines in the Caribbean, as in many parts of the world. This is confirmed in a recent pilot 
study done in which 80% of prescription medicine consumers also take natural remedies 
(Delgoda et al., 2004; Picking et al., 2011). Also, adverse drug reactions (ADRs) accumulates 
to over 2 million per year in the United States alone (Gurwitz et al., 2000), therefore, the 
ability to predict drug interactions involving the CYP enzymes has become a key component 
of the drug discovery process (Forti and Wahlstrom, 2008). Providing the FDA with the 
metabolic profile of a new drug entity with CYP enzymes is the first step towards avoiding 
adverse reactions (Delgoda and Westlake, 2004). Known drug –herb interactions with 
clinical impact include grapefruit juice with felopidium, tricyclic anti depressants which is 
medicated through CYP3A4 inhibition. 
We report for the first time hot water infusions of Rhytidophyllum tomentosa, Psidium guajava, 
Symphytium officinale, Momordica charantia in comparison with reported Picrasma excelsa 
being tested against CYP enzymes activity. The greatest potency was observed in the 
presence of Psidium guajava that inhibited CYP1A1 with an IC50 of 4.9µg/mL. All of the 
infusions are commonly consumed, be it, the fruit or as teas. With the high levels of 
polypharmacy practise that exist among Caribbean people and the world, having a 
metabolic profile on teas or commonly consumed plants become of grave importance. 
Results displayed in Table 3 point to is minimal risk through CYP mediated drug 
interactions as the teas weakly inhibited the main drug metabolising enzymes. Because, the 
activity of Psidium guajava towards CYP1A1 was the most potent we further evaluated the 
identification of the active ingredients that could be responsible for the observed bioactivity 
towards the CYP1A1 activity. The active ingredients were found to be quercetin and 
hyperin (see Figs. 4 & 5), compounds known as inhibitors of CYP enzymes, where quercetin 
isolated from St. John’s Wort has been previoulsy shown to inhibit activities of CYPs 1A2, 
2C19 and CYP2D6 with IC50s of 3.87 µM, 6.23 µM and 20.99 µM respectively; while 
hyperforin isolated from Ginko biloba shown to inhibit the activity of CYP3A4 with an IC50 of 
4.30µM (Moltke et al., 2004; Zou et al., 2002). Inhibitions against the CYP enzymes appear to 
be between moderate and weak which confirms data in our lab, thus evoking moderate 
concern for potential interactions with co-medicated pharmaceuticals through CYP 
mediated metabolism.  
5. Conclusion 
Review of compounds that have potent and selective inhibitory properties against the 
activities of CYP1 family in particular CYPs 1A1 and 1B1 aid in identification of useful 
chemoprotectors. CA1 and quassin warrant further research because they were both 
potent against the activity of CYP1A1 while anhydrosorbifolin and chroma 6 targeted 
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CYP1B1. In vitro and in silico models as demonstrated for the first time in this chapter are 
useful tools in the process of drug development to approximate the risk of drug 
interactions and in the process of target improvement of key enzymes in 
chemoprevention. In particular, for herbal remedies they confer useful models for 
evaluating the risks of adverse effects arising from interactions with co-administered 
prescription medicines, for which drug-interaction information is not mandated by the 
regulatory agencies. Once the initial risk is estimated, clinical drug-interaction studies can 
be launched, thus providing a cost-effective sieving process prior to embarking on 
rigorous and expensive investigations.  
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